Skip to main content

Peer Review reports

From: Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic

Original Submission
16 Dec 2024 Submitted Original manuscript
20 Dec 2024 Author responded Author comments - Sakiko Kimura
Resubmission - Version 2
20 Dec 2024 Submitted Manuscript version 2
24 Dec 2024 Author responded Author comments - Sakiko Kimura
Resubmission - Version 3
24 Dec 2024 Submitted Manuscript version 3
4 Jan 2025 Reviewed Reviewer Report
6 Jan 2025 Reviewed Reviewer Report
8 Jan 2025 Reviewed Reviewer Report - Shutao Zheng
22 Mar 2025 Author responded Author comments - Sakiko Kimura
Resubmission - Version 4
22 Mar 2025 Submitted Manuscript version 4
25 Mar 2025 Author responded Author comments - Sakiko Kimura
Resubmission - Version 5
25 Mar 2025 Submitted Manuscript version 5
26 Mar 2025 Author responded Author comments - Sakiko Kimura
Resubmission - Version 6
26 Mar 2025 Submitted Manuscript version 6
28 Mar 2025 Reviewed Reviewer Report
28 Mar 2025 Reviewed Reviewer Report
2 Apr 2025 Reviewed Reviewer Report
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
3 Apr 2025 Editorially accepted
16 Apr 2025 Article published 10.1186/s12865-025-00711-w

You can find further information about peer review here.

Back to article page